99mTc-MIBI全身显像及P糖蛋白预测中晚期 非小细胞肺癌患者多药的耐药性.

Objectives To evaluate the 99mTcMIBI whole body scintigraphy（WBS） and P-glycoprotein （PGP） in the prediction of multiple drug resistance（MDR） in the mid-late stage NSCLC patients in a half-year follow-up. Methods 57 patients with mid-late stage NSCLC（39 male，18 female，with a mean age of 59.5± 14.7 years） entered the study. 20 patients had no previous history of treatment and 37 had a history of previous chemo-radiotherapy. All patients underwent PET/CT imaging before the initial diagnosis or treatment，and the primary lesion or metastasis was confirmed by pathology as NSCLC （31 adenocarcinoma， 26 squamous cell carcinoma） . WBS and measurements of PGP were performed before initialization of treatment and the response to treatment was assessed by PET/CT after six months. The WBS was considered positive when at least one area of non-physiologic increased activity was noted. The presence of MDR was indicated when the patient had active disease but the WBS was negative．Results For WBS，the sensitivity， specificity， positive predictive value， negative predictive value and accuracy in NSCLC patients for the prediction of MDR were 40%、73.7% 、70.6% 、43.8% and 57.1%， respectively. Also the above values for PGP were 50%、52.6% 、65.2% 、38.5% and 51.0%， respectively. The risk of MDR in WBS negative patients was 1.25 times （0.60-1.72） higher than that in the WBS positive patients. Conclusion The value of WBS and PGP in the prediction of MDR in the mid-late stage NSCLC patients was limited. Studies using the method of WBS combined with PGP and including more samples may require further discussion. [ABSTRACT FROM AUTHOR]